SCHEMBL4814653

SCHEMBL4814653

[CH2]/C=C\c1cnc2ccccc2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 4/20 0.71
PDGFRA P16234 4/20 0.71
RAB9A P51151 3/20 0.61
KDM4E B2RXH2 2/20 0.55
KMT2A Q03164 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
CYP1A2 P05177 2/20 0.48
ALDH1A1 P00352 7/20 0.46
GAA P10253 2/20 0.46
MAPT P10636 2/20 0.46
LMNA P02545 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
MGAM O43451 1/20 0.43
ADORA2A P29274 1/20 0.43
CYP2A6 P11509 1/20 0.41
HPGD P15428 2/20 0.40
BIRC5 O15392 1/20 0.40
GLA P06280 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL372291 1.00 PDGFRB (0.71) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL372292 1.00 PDGFRB (0.71) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL563573 0.83 PDGFRB (0.73) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL3164863 0.83 PDGFRB (1.00) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL3164867 0.83 PDGFRB (1.00) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL563572 0.83 PDGFRB (0.73) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL5459685 0.81 PDGFRB (0.71) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL7668269 0.81 PDGFRB (0.71) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL9000566 0.81 PDGFRB (0.77) PDGFRBPDGFRARAB9AKDM4EKMT2A
SCHEMBL9000561 0.81 PDGFRB (0.77) PDGFRBPDGFRARAB9AKDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US claimed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US claimed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP claimed
US-7365174-B2 Azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2008-04-29 US disclosed
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same MEIJI SEIKA KAISHA, LTD. (JP) 2007-02-22 US disclosed
EP-1661904-A1 NOVEL AZALIDE AND AZALACTAM DERIVATIVES AND PROCESS FOR THE PRODUCTION OF THE SAME MEIJI SEIKA KAISHA LTD. (JP) 2006-05-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070042974-A1 Nozel azalide and azalactam derivatives and method for producing the same BCL6, NR4A1, NR4A2 PDGFRB 2207/4885PDGFRA 2360/4885RAB9A 2161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.